Insider Trading Activity Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – EVP Sold 6,459 shares of Stock

Insider Trading Activity For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stuart A Arbuckle , EVP of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reportedly Sold 6,459 shares of the company’s stock at an average price of 169 for a total transaction amount of $1,091,571.00 SEC Form

Insider Trading History For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

On 9/5/2012 Joshua S Boger, Director, sold 4,000 with an average share price of $54.70 per share and the total transaction amounting to $218,800.00.

On 10/3/2012 Joshua S Boger, Director, sold 4,000 with an average share price of $57.74 per share and the total transaction amounting to $230,960.00.

On 10/8/2012 Ian F Smith, CFO, sold 44,787 with an average share price of $60.00 per share and the total transaction amounting to $2,687,220.00.

On 11/7/2012 Margaret G Mcglynn, Director, bought 1,000 with an average share price of $45.50 per share and the total transaction amounting to $45,500.00.

On 12/26/2012 Joshua S Boger, Director, sold 4,000 with an average share price of $41.86 per share and the total transaction amounting to $167,440.00.

On 5/14/2013 Bruce I Sachs, Director, sold 60,000 with an average share price of $81.15 per share and the total transaction amounting to $4,869,000.00.

On 5/15/2013 Joshua S Boger, Director, sold 1,400 with an average share price of $79.36 per share and the total transaction amounting to $111,104.00.

Analyst Ratings History For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

• On 3/28/2016 Guggenheim Lower Price Target of rating Buy with a price target of $145.00 to $114.00
• On 4/28/2016 Goldman Sachs Group Downgraded rating Buy to Neutral with a price target of $109.00 to $88.00
• On 11/1/2016 William Blair Downgraded rating Outperform to Market Perform with a price target of $105.00 to $81.00
• On 6/2/2017 CIBC Upgraded rating Market Perform to Outperform
• On 7/18/2017 Stifel Nicolaus Boost Price Target of rating Buy to Buy with a price target of $130.00 to $154.00
• On 7/19/2017 Janney Montgomery Scott Upgraded rating Neutral to Buy with a price target of $98.00
• On 7/19/2017 Raymond James Financial Upgraded rating Market Perform to Outperform with a price target of $181.00

Dividend History For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

On 1/29/2013 Vertex Pharmaceuticals Incorporated announced a quarterly dividend of $0.40 with an ex dividend date of which will be payable on 3/13/2013.

Recent Trading Activity for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Shares of Vertex Pharmaceuticals Incorporated closed the previous trading session at 168.45 up +2.57 1.55% with 166.6999969482422 shares trading hands.